ETFChannel.com
BMY Description — Bristol Myers Squibb Co.

Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.

Company Name: 
Bristol Myers Squibb Co.
Website: 
www.bms.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding BMY: 
128
Total Market Value Held by ETFs: 
$20,770,352,526.08
Total Market Capitalization: 
$159,205,000,000
% of Market Cap. Held by ETFs: 
13.05%
 ETF   BMY Weight   BMY Amount 
 VTI   0.38%   $4,722,919,265         
 VOO   0.44%   $3,560,912,284         
 SPY   0.44%   $1,722,150,220         
 IVV   0.44%   $1,412,383,219         
 VTV   0.92%   $1,385,852,502         
 XLV   3.21%   $1,276,942,196         
 VIG   1.29%   $1,007,934,554         
 VYM   1.11%   $667,189,407         
 VHT   2.82%   $551,922,494         
 IWD   0.82%   $451,811,119         
List of all 128 ETFs holding BMY »
Quotes delayed 20 minutes

Email EnvelopeFree BMY Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Buy (2.86 out of 4)
12nd percentile
(ranked lower than approx. 88% of all stocks covered)

Analysts Forecast:
BMY Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding BMY | Bristol Myers Squibb Co. | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2022, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.